Home » News and Events » News

A NEW WEBSITE FOR IRIS PHARMA

July 3, 2008 - We are pleased to announce the launch of our new website www.iris-pharma.com

More concise, more user-friendly, and with a fresh and dynamic new look, the new website offers each visitor access to useful information on the company, its services and activities, news and publications. Along with enhanced navigation and usability, the new website also offers a focus in ophthalmology and becomes a key portal to communicate Iris Pharma's unique expertise and experience.

The website will be regularly updated with new information and upcoming events so make sure to visit us often!

 

NEW PARIS PREMISES AT THE INSTITUT DE LA VISION

December 9, 2008 - Iris Pharma opens its new Paris (FRANCE) premises at the Institut de la Vision, one of Europe's major research centers dedicated to eye diseases. This collaboration will facilitate the accelerated development of new therapies to benefit patients with impaired vision and suffering from ocular ailments. Read the press release. Lire le communiqué de presse.

 

PARTNERSHIP

July 3, 2008 - The Institut de la Vision and Iris Pharma join forces to strengthen the bond between the private and public sectors, and between industry and academic research […] Read the press release

 

MERGER

December 11, 2007 - Iris Pharma, a specialist CRO for pre-clinical research in ophthalmology, has announced the completion of its merger with Clirophtha, a unique CRO in Europe and North America that is completely dedicated to ophthalmology clinical trials […] Read the press release

PEOPLE

December 1st, 2007 - Dr Mustapha Benchaboune joined Iris Pharma's clinical services staff on November 1st, 2007 as a Medical Director […] Read the press release

NEW ANIMAL MODELS

• The Iris Pharma Research Team has developed a new rat Experimental Autoimmune Uveitis (EAU) model to add to its catalogue of animal models of ocular inflammation for preclinical testing in the field of ophthalmology. Experimental Autoimmune Uveitis (EAU) is an organ-specific autoimmune disease and serves as a model of certain ocular inflammatory pathologies in human.
• The Iris Pharma Research Team has validated several animal models to investigate the various aspects of Age-related Macular Degenerescence (AMD) and retinal degenerescence: corneal angiogenesis (suture model on rabbits), retinopathy of prematurity (ROP, hyperoxia model in pup mice), chemical burn (alcohol, sodium hydroxyde models in rats, mice and rabbits), retinal vascular permeability (VEGF-induced leakage) in rabbits and choroidial neovascularization (CNV) model. Read the press release
• Our Research Department never stops exploring. In vivo animal models related to diabetic retinopathy and glaucoma are currently under development.

   

NEW METHODS

• Evaluation of the volume of the lesion in the Choroidal Neovascularization (CNV) using endothelial cell specific staining (anti-isolectine B4).
• Evaluation of animal model allergic conjunctivitis using in vivo confocal microscopy (HRTII) and conjunctival impression cytology collection.

 

NEW ANIMAL HUSBANDRY

December 27, 2007 - Due to the steady increase in demand for its services, Iris Pharma has decided to expand its animal housing facility […] Read the press release

ACQUISITIONS (APPARATUS)

• Acquisition of a new RRLC-MS/MS system for clearly superior results in bioanalysis
  After a one-year trial period, Iris Pharma had acquired the Agilent 6410 triple quadrupole LCMS. This system dramatically increases the speed of analysis, the volume of sample and the sensitivity and brings the highest level of performance and reliability to Iris Pharma labs.
• Counter beta Tri-Carb 2900 (Perkin Elmer): liquid scintillation analyzer. This instrument measures levels of radioactive elements by counting photonic emissions produced when alpha and beta particles interact with certain reagents (scintillants).
• Cyclone Plus Phosphor Imager: radiometric phosphor imager for quantitative filmless autoradiography. ApoTome: light microscope using "structured illumination" process for 3D fluorescence imaging.

COMMITMENT

February, 2008 - Establishment of Ophta Biotech
Iris Pharma is one of the co-founders of this new French organization which aims at gathering the French Riviera, Corsica and Monaco-based experts, doctors, industries, researchers, patients organizations and others who have a concern in ophthalmology to better promote the local expertise and know-how in this field around the world.